Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.
Endometrial cancer is one of the most common gynecological cancers. Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition. The investigators tested the hypothesis that short-term presurgical metformin reduces cellular proliferation in endometrial cancer. However, no good quality of evidence base supports the effectiveness of metformin for deceasing proliferative marker in endometrial cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Regular strength metformin (850 mg/tab)
Starch based placebo manufatured to mimic Metformin 850 mg
Rajavithi Hospital
Bangkok, Bangkok, Thailand
Change of Ki-67 expression in endometrial tumor
metformin administration reduced Ki-67 expression in endometrial tumor when given for 4 weeks before hysterectomy.
Time frame: 4 weeks
Change of grade in endometrial tumor
metformin administration reduced grade in endometrial tumor when given for 4 weeks before hysterectomy.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.